natgillin/translations-raw huggingface dataset:
Patients were given either six cycles of Pixuvri or another approved anticancer medicine chosen by their doctor. 
Bolniki so prestali šest krogov zdravljenja z zdravilom Pixuvri ali drugim odobrenim zdravilom proti raku, ki ga je izbral njihov zdravnik.
What benefit has Pixuvri shown during the studies? 
Kakšne koristi je zdravilo Pixuvri izkazalo med študijami?
Pixuvri was shown to be beneficial in patients with aggressive non-Hodgkin's B cell lymphoma: 20% of patients responded completely to Pixuvri (14 out of 70 patients) compared with 5.7% of patients receiving other agents (4 out of 70 patients). 
Zdravilo Pixuvri je izkazalo koristen učinek pri bolnikih z agresivnim ne-Hodgkinovim B-celičnim limfomom: 20 % bolnikov se je popolnoma odzvalo na zdravljenje z zdravilom Pixuvri (14 od 70 bolnikov) v primerjavi s 5,7 % bolnikov, ki so dobivali druge učinkovine (4 od 70 bolnikov).
This means that the cancer cells in non-Hodgkin's B cell lymphoma cannot divide and eventually die. 
To pomeni, da se rakaste celice neHodgkinovega B-celičnega limfoma ne morejo deliti in sčasoma odmrejo.
However, the Committee noted that more data were needed on the benefits of Pixuvri in patients who have received previous treatment with rituximab (another medicine commonly used to treat lymphoma). 
Vendar je opozoril, da je potrebnih več podatkov o koristih zdravila Pixuvri pri bolnikih, ki so se prej zdravili z rituksimabom (drugim zdravilom, ki se pogosto uporablja za zdravljenje limfoma).
Pixuvri is used to treat adult patients with non-Hodgkin's B cell lymphoma. 
Pixuvri se uporablja za zdravljenje odraslih bolnikov z ne-Hodgkinovim B-celičnim limfomom.
Pixuvri must be given by a doctor who has experience in the use of anticancer medicines and who has access to facilities for monitoring the patient. 
Zdravilo Pixuvri sme dajati samo zdravnik, ki ima izkušnje z uporabo zdravil proti raku in ima dostop do opreme za spremljanje bolnikov.
Pixuvri can be given for up to six cycles. 
Zdravilo Pixuvri se lahko uporablja v največ šestih krogih zdravljenja.
The active substance in Pixuvri, pixantrone, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anthracyclines'. 
Zdravilna učinkovina v zdravilu Pixuvri, piksantron, je citotoksično zdravilo (zdravilo, ki uničuje celice, ki se delijo, na primer rakaste celice), ki spada v skupino „antraciklinov“.
What is the risk associated with Pixuvri? 
Kakšna tveganja so povezana z zdravilom Pixuvri?
The company that makes Pixuvri will carry out a study to further investigate the effects of using Pixuvri in patients who had received prior treatment with rituximab. 
Družba, ki izdeluje zdravilo Pixuvri, bo opravila študijo, s katero bo dodatno raziskala učinke zdravljenja z zdravilom Pixuvri pri bolnikih, ki so se prej zdravili z rituksimabom.
Pixuvri is used when the lymphoma is aggressive and has come back or has not responded to other chemotherapy treatments (medicines to treat cancer). 
Zdravilo Pixuvri se uporablja, kadar je limfom agresiven in se je ponovil ali se ni odzval na zdravljenje z drugimi kemoterapevtiki (zdravili proti raku).
Pixuvri is a medicine that contains the active substance pixantrone. 
Pixuvri je zdravilo, ki vsebuje zdravilno učinkovino piksantron.
For the full list of all side effects reported with Pixuvri, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Pixuvri, glejte navodilo za uporabo.
Pixuvri must not be used in patients who are hypersensitive (allergic) to pixantrone or any of the other ingredients. 
Zdravila Pixuvri ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) piksantron ali katero koli drugo sestavino zdravila.
The CHMP also considered the seriousness of the disease and the lack of suitable alternative treatments for patients whose non-Hodgkin's B cell lymphoma has come back or has not responded to other chemotherapy treatments. 
Odbor CHMP je upošteval tudi resnost bolezni in pomanjkanje ustreznih nadomestnih zdravil za bolnike, pri katerih se je neHodgkinov B-celični limfom ponovil ali se ni odzval na zdravljenje z drugimi kemoterapevtiki.
What information is still awaited for Pixuvri? 
Katere informacije o zdravilu Pixuvri še pričakujemo?
The CHMP concluded that patients with aggressive non-Hodgkin's B cell lymphoma had a better response to treatment with Pixuvri than other cancer treatments. 
Odbor CHMP je zaključil, da so se bolniki z agresivnim ne-Hodgkinovim B-celičnim limfomom bolje odzvali na zdravilo Pixuvri kot na druga zdravila proti raku.
Why has Pixuvri been approved? 
Zakaj je bilo zdravilo Pixuvri odobreno?
What is Pixuvri used for? 
Za kaj se zdravilo Pixuvri uporablja?
How has Pixuvri been studied? 
Kako je bilo zdravilo Pixuvri raziskano?
What is Pixuvri? 
Kaj je zdravilo Pixuvri?
Pixuvri was compared with other chemotherapy treatments in one main study involving 140 adults with aggressive non-Hodgkin's B cell lymphoma, who had previously received at least two other treatments, and whose cancer had come back or had not responded to treatment. 
V eni glavni študiji, ki je zajela 140 odraslih z agresivnim ne-Hodgkinovim B-celičnim limfomom, ki so se predhodno zdravili z vsaj dvema drugima zdraviloma in pri katerih se je rak ponovil ali se ni odzval na zdravljenje, so zdravilo Pixuvri primerjali z drugimi kemoterapevtiki.
How is Pixuvri used? 
Kako se zdravilo Pixuvri uporablja?
How does Pixuvri work? 
Kako zdravilo Pixuvri deluje?
Pixuvri has been given ‘conditional approval'. 
Zdravilo je pridobilo tako imenovano „pogojno dovoljenje za promet“.
The full EPAR and risk management plan summary for Pemetrexed medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Pemetreksed medac sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Pemetrexed medac? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pemetreksed medac?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed medac has been shown to be comparable to Alimta. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Pemetreksed medac primerljivo z zdravilom Alimta.
This is a summary of the European public assessment report (EPAR) for Pemetrexed medac. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pemetreksed medac.
The Committee recommended that Pemetrexed medac be approved for use in the EU. 
Priporočil je, da se zdravilo Pemetreksed medac odobri za uporabo v EU.
This means that Pemetrexed medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Alimta.
Because Pemetrexed medac is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Pemetreksed medac generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
What are the benefits and risks of Pemetrexed medac? 
Kakšne so koristi in tveganja, povezani z zdravilom Pemetreksed medac?
Pemetrexed medac is a cancer medicine used to treat two types of lung cancer: 
Zdravilo Pemetreksed medac je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje dveh vrst pljučnega raka:
What is Pemetrexed medac and what is it used for? 
Kaj je zdravilo Pemetreksed medac in za kaj se uporablja?
A risk management plan has been developed to ensure that Pemetrexed medac is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Pemetreksed medac je bil pripravljen načrt obvladovanja tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed medac, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For practical information about using Pemetrexed medac, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Pemetreksed medac naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed medac. 
Da bi zmanjšali neželene učinke, morajo bolniki med zdravljenjem z zdravilom Pemetreksed medac jemati kortikosteroid (vrsto zdravila, ki ublaži vnetje) in folno kislino (vrsto vitamina) ter prejemati injekcije vitamina B12.
For more information about treatment with Pemetrexed medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Pemetreksed medac preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It is not intended to provide practical advice on how to use Pemetrexed medac. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Pemetrexed medac is a ‘generic medicine'. 
Zdravilo Pemetreksed medac je „generično zdravilo“.
Other information about Pemetrexed medac 
Druge informacije o zdravilu Pemetreksed medac
When Pemetrexed medac is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose. 
Kadar se zdravilo Pemetreksed medac daje v kombinaciji s cisplatinom, je treba pred odmerkom cisplatina ali po njem bolniku dati tudi „antiemetično“ zdravilo (za preprečevanje bruhanja) in tekočino (za preprečevanje dehidracije).
The active substance in Pemetrexed medac, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'. 
Zdravilna učinkovina v zdravilu Pemetreksed medac, pemetreksed, je citotoksik (zdravilo, ki uničuje celice, ki se delijo, kot na primer rakave celice) iz skupine „antimetabolitov“.
Pemetrexed medac is available as a powder that is made up into a solution for infusion (drip) into a vein. 
Zdravilo Pemetreksed medac je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalna infuzija) v veno.
Pemetrexed medac pemetrexed 
Pemetreksed medac pemetreksed
Why is Pemetrexed medac approved? 
Zakaj je bilo zdravilo Pemetreksed medac odobreno?
Pemetrexed medac contains the active substance pemetrexed. 
Zdravilo Pemetreksed medac vsebuje zdravilno učinkovino pemetreksed.
How has Pemetrexed medac been studied? 
Kako je bilo zdravilo Pemetreksed medac raziskano?
How does Pemetrexed medac work? 
Kako zdravilo Pemetreksed medac deluje?
No additional studies were needed as Pemetrexed medac is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta. 
Ker je zdravilo Pemetreksed medac generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Alimta, niso bile potrebne nobene dodatne študije.
How is Pemetrexed medac used? 
Kako se zdravilo Pemetreksed medac uporablja?
Results at week 16 
Rezultati v 16. tednu
Outcomes a 
Izid a
The reason for this is not known. 
Vzrok tega ni znan.
Taking/using other medicines 
Jemanje/uporaba drugih zdravil
Date of last renewal: 17 November 2005 
Datum zadnjega podaljšanja dovoljenja za promet: 17. november 2005
• Other combinations 
• Druge kombinacije
Clinical experience: 
Klinične izkušnje:
For this reason, it is very important that you inform your doctor about any changes in your health. 
Tako je nadvse pomembno, da svojega zdravnika obvestite prav o vsaki spremembi svojega zdravstvenega stanja.
The mechanism of this interaction remains unknown. 
Mehanizem tega medsebojnega delovanja ostaja neznan.
You should keep in regular contact with your doctor. 
S svojim zdravnikom morate biti v rednem stiku.
In some patients, additional factor VIII was given. 
Nekateri bolniki so dodatno dobivali faktor VIII.
In children, the nature of the safety profile is similar to that seen in adults. 
Pri otrocih je narava varnostnega profila podobna tistemu pri odraslih.
The clinical significance of these possible interactions is not known and has not been investigated. 
Klinični pomen teh morebitnih interakcij ni znan in ga niso preučevali.
Stevens Johnson syndrome 
Stevens-Johnsonov sindrom
You should tell your doctor about any medical conditions that you have or have had. 
Svojemu zdravniku morate povedati za vsako zdravstveno težavo, ki jo imate ali ste jo kdaj imeli.
You can still continue to develop other infections and other illnesses associated with HIV disease. 
Še vedno lahko prihaja do drugih okužb in bolezni, ki so povezane z okužbo z virusom HIV.
These medicines are used for treating human immunodeficiency virus (HIV) infection. 
Ta zdravila se uporabljajo za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV).
A second peak is observed after 10 to 12 hours and may represent either delayed absorption or enterohepatic recirculation. 
Drugi vrh koncentracij so opazili po 10-12 urah in lahko predstavlja bodisi zapoznelo absorpcijo bodisi enterohepatično recirkulacijo.
The dose of amprenavir may need adjusting. 
Odmerek amprenavirja bo morda potrebno prilagoditi.
Elimination: the plasma elimination half-life of amprenavir ranges from 7.1 to 10.6 hours. 
Izločanje: Plazemski razpolovni čas izločanja znaša za amprenavir od 7,1 do 10,6 ur.
The potential risk to humans is unknown. 
Možno tveganje za ljudi ni znano.
DATE OF THE REVISION OF THE TEXT Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu 
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http://www.emea.europa.eu/.
Treatment difference 
Razlika v zdravljenju
The clinical relevance of these changes is unknown. 
Klinični pomen teh sprememb ni poznan.
These capsules also contain sorbitol. 
Kapsule vsebujejo tudi sorbitol.
On rare occasions, these muscle disorders have been serious (rhabdomyolysis). 
V redkih primerih so bile te mišične težave resne (rabdomioliza).
1.0 (range 0-2) 
1,0 (razpon 0-2)
Of note, the following interaction data was obtained in adults. 
Upoštevati je potrebno naslednje podatke o interakcijah, ki so bili pridobljeni pri odraslih.
BATCH NUMBER LOT 
ŠTEVILKA SERIJE Lot
You should not take more than 2400 mg per day. 
Na dan pa ne smete vzeti več kot 2400 mg.
Pregnancy: there are no adequate data from the use of amprenavir in pregnant women. 
Nosečnost: Ni zadostnih podatkov o uporabi amprenavirja pri nosečnicah.
Amprenavir did not affect fertility. 
Amprenavir ni prizadel plodnosti.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 October 2000 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 20. oktober 2000
The mechanism for the hepatocellular adenomas and carcinomas found in these studies has not been elucidated and the significance of the observed effects for humans is uncertain. 
Mehanizem nastanka hepatocelularnih adenomov in karcinomov, ki so bili ugotovljeni v teh študijah, ni pojasnjen, pomen opaženih učinkov pa je za človeka nezanesljiv.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch 
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sproščanje zadevne serije.
If you forget to take a dose of Agenerase, take it as soon as you remember and then continue as before. 
Če ste pozabili vzeti odmerek zdravila Agenerase, ga vzemite takoj, ko se spomnite, in nato nadaljujte kakor poprej.
• Swelling of the face, lips and tongue (angioedema) 
• Otekanje obraza, ustnic in jezika (angioedem).
Clearance also decreased in a corresponding manner to the AUC. 
V ustreznem razmerju z AUC se je zmanjšal tudi očistek.
Note that the background rates in comparator groups were not taken into account. 
Upoštevati je potrebno, da podatki primerjalnih skupin niso všteti.
In some of these, the hyperglycaemia was severe and in some cases also associated with ketoacidosis. 
Pri posameznikih je bila hiperglikemija huda in v nekaterih primerih povezana s ketoacidozo.
Elevations in cholesterol were of grade 3-4 intensity. 
Zvišanje vrednosti holesterola je bilo stopnje 3-4.
(−21, 9)c a Intent To Treat (Exposed) Population: Observed analysis b Mean stratified difference c 95% confidence interval 
(−21, 9)c a Vključeni (izpostavljeni) bolniki: opazovalna analiza b Srednja stratificirana razlika c 95 % interval zaupanja
Median number of PI primary mutations 1 
Srednje število primarnih mutacij PIjev 1
This medicinal product should be used during pregnancy only after careful weighing of the potential benefits compared to the potential risk to the foetus. 
Zdravilo se sme med nosečnostjo uporabljati le po temeljitem razmisleku o potencialnih koristih v primerjavi s potencialnim tveganjem za plod.
Conclusions regarding the relevance of particular mutations or mutational patterns are subject to change with additional data, and it is recommended to always consult current interpretation systems for analysing resistance test results. 
Izsledki o pomenu določenih mutacij ali mutacijskih vzorcev so predmet dopolnjevanja z dodatnimi podatki, zato priporočamo, da pri analiziranju rezultatov rezistenčnih testov vedno upoštevate najnovejše interpretacijske sisteme.
Do not take a double dose to make up for forgotten individual doses. 
Ne vzemite dvojnega odmerka, da bi nadoknadili pozabljeni posamični odmerek.
Appropriate precautions should continue to be taken. 
Še naprej je potrebno kontinuirano skrbeti za ustrezne varnostne ukrepe.
Patients with rare hereditary problems of fructose intolerance should not take this medicine. 
Bolniki s hereditarno intoleranco za fruktozo tega zdravila ne smejo jemati.
In pregnant mice, rabbits and rats there were no major effects on embryo-foetal development. 
Pri brejih miših, podganah in kunčicah ni bilo večjih učinkov na embriofetalni razvoj.
Other possible interactions 
Druge možne interakcije
The absolute bioavailability is unknown due to the lack of an acceptable intravenous formulation for use in man. 
Absolutna biološka uporabnost ni znana zaradi pomanjkanja primerne intravenske oblike, ki bi jo lahko uporabljali pri ljudeh.
No studies on the effects on ability to drive and use machines have been performed (see section 4.8). 
Študije o vplivu na sposobnost vožnje in upravljanja s stroji niso bile izvedene (glejte poglavje 4.8).
Clinical examination should include evaluation for physical signs of fat redistribution. 
Klinični pregled mora obsegati oceno telesnih znakov prerazdelitve maščevja.
• A severe or life-threatening skin reaction (Stevens Johnson syndrome) 
• Hude ali smrtno nevarne kožne reakcije (Stevens-Johnsonov sindrom).
Antibiotics/antifungals 
Antibiotiki/antimikotiki
Do not take a double dose to make up for a forgotten dose. 
Ne vzemite dvojnega odmerka, da bi nadoknadili pozabljeni odmerek.
If your liver disease is severe you must not use this combination. 
Če imate hudo jetrno bolezen, takšne kombinacije ne smete uporabljati.
• Moodiness, depression, difficulty sleeping, loss of appetite 
• Slabovoljnost, depresija, težave s spanjem, izguba apetita.
The concentration of amprenavir in the cerebrospinal fluid is less than 1 % of plasma concentration. 
Koncentracija amprenavirja v cerebrospinalni tekočini znaša manj kot 1 % njegove plazemske koncentracije.
Toxicity studies in young animals, treated from four days of age, resulted in high mortality in both the control animals and those receiving amprenavir. 
Študije toksičnosti pri mladičih, ki so dobivali zdravila od četrtega dneva starosti, so pokazale visoko stopnjo umrljivosti tako pri živalih v kontrolni skupini kot pri tistih, ki so prejemale amprenavir.
While administration of amprenavir with food results in a 25 % reduction in AUC, it had no effect on the concentration of amprenavir 12 hours after dosing (C12). 
Čeprav zaužitje amprenavirja s hrano zmanjša AUC za 25 %, hrana nima vpliva na koncentracijo amprenavirja 12 ur po zaužitju odmerka (C12).
In this situation, a reduced dose of atorvastatin should be considered. 
V tem primeru je potrebno razmisliti o zmanjšanju odmerka atorvastatina.
Associations contraindicated (see section 4.3) 
Povezave s kontraindikacijami (glejte poglavje 4.3)
Lactation: amprenavir-related material was found in rat milk, but it is not known whether amprenavir is excreted in human milk. 
Dojenje: V podganjem mleku so zasledili amprenavirju sorodne snovi, vendar ni znano, ali se amprenavir izloča v človeško mleko.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products. 
V primeru sočasnega protivirusnega zdravljenja hepatitisa B ali C je potrebno upoštevati tudi relevantne podatke o teh zdravilih.
SOC PI (n = 83): Indinavir / RTV (29%) Lopinavir / RTV (36%) Saquinavir / RTV(20%) 
Standardno zdravljenje s PI-ji (n = 83): Indinavir / RTV (29 %) Lopinavir / RTV (36 %) Sakvinavir / RTV(20 %)
Analyses based on genotypic resistance testing. 
Analize na osnovi genotipskega testiranja rezistence
In in vitro studies, the protein binding of amprenavir is approximately 90 %. 
V in vitro študijah je vezava amprenavirja na proteine približno 90 %.
A 20 ml measuring cup is provided, to help you measure out the correct amount of oral solution for each dose. 
Zdravilu je priložen 20 ml merilni lonček, ki vam bo pomagal pri odmerjanju pravilnih količin peroralne raztopine vsakega odmerka.
Glycerol can cause headache, stomach upset and diarrhoea. 
Glicerol lahko povzroči glavobol, želodčne motnje in drisko.
Agenerase may interact with other medicines that you are taking, so it is important that you read the next section “Taking/using other medicines” before taking this medicine. 
Učinek zdravila Agenerase se lahko prepleta z učinki drugih zdravil, ki jih jemljete, zato je pomembno, da, preden vzamete to zdravilo, preberete poglavje “Jemanje/uporaba drugih zdravil” v nadaljevanju tega navodila.
If you forget to take Agenerase 
Če ste pozabili vzeti zdravilo Agenerase
Itraconazole concentrations are expected to increase in the same manner as ketoconazole. 
Pričakuje se, da bi se koncentracije itrakonazola zvišale podobno kot koncentracije ketokonazola.
Limited experience with Agenerase oral solution indicate a similar safety profile as for the capsules. 
Omejene izkušnje s peroralno raztopino Agenerase indicirajo podoben varnostni profil, kot je pri kapsulah.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. 
Če se pri takšnih bolnikih pojavijo znaki poslabšanja jetrne bolezni, je potrebno razmisliti o začasni prekinitvi ali dokončni ukinitvi zdravljenja.
They can be taken with or without food. 
Lahko jih jemljete skupaj s hrano ali brez nje.
Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered. 
Razmisliti je treba o prilagoditvi odmerka midazolama, še posebej v primeru, če je potreben več kakor en odmerek midazolama.
Amprenavir is primarily bound to the alpha-1-acid glycoprotein (AAG), but also to albumin. 
Amprenavir se primarno veže na kisli glikoprotein alfa-1 (AAG), vendar tudi na albumin.